8-K: Ocular Therapeutix Reports Q1 2025 Results: AXPAXLI Trials Progress, Cash Runway Extends into 2028

Ocular Therapeutix announced its Q1 2025 financial results, highlighting progress in AXPAXLI clinical trials for wet AMD and NPDR, and a strong cash position expected to last into 2028.

Summary

• Ocular Therapeutix reported a net revenue of $10.7 million for Q1 2025, a 27.6% decrease compared to $14.8 million in Q1 2024, primarily due to decreased DEXTENZA sales.
• The company's net product revenue from DEXTENZA was $10.6 million, a 27.7% decrease year-over-year.
• The company anticipates that net product revenue on a quarterly basis should increase for the remainder of 2025, driven primarily by expected increases in the number of units sold.
• Research and development expenses increased to $42.9 million from $20.7 million in the same quarter last year, driven by the SOL-1 and SOL-R Phase 3 clinical trials.
• Selling and marketing expenses rose to $14.1 million from $10.2 million, reflecting pre-commercialization activities for AXPAXLI.
• The net loss for Q1 2025 was $(64.1) million, or $(0.38) per share, compared to a net loss of $(64.8) million, or $(0.49) per share, for Q1 2024.
• As of March 31, 2025, Ocular Therapeutix had $349.7 million in cash and cash equivalents.
• The company expects its cash balance to be sufficient to fund operations into 2028, including through topline data for SOL-1 and SOL-R.
• The SOL-1 trial for wet AMD is on track for a Q1 2026 topline data readout.
• Enrollment in the SOL-R trial for wet AMD continues to be strong after reducing the target randomization to approximately 555 subjects.
• The FDA provided positive feedback on a potential registrational trial design for AXPAXLI in NPDR, and the company is actively planning next steps in NPDR and DME.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue is down, the company has a strong cash position and is making progress in its clinical trials. The positive FDA feedback on the NPDR trial is also encouraging.

Positives

• The company has a strong cash position of $349.7 million, providing a runway into 2028.
• The SOL-1 trial is on track for a Q1 2026 topline data readout, and the FDA accepted an amendment to the SOL-1 Special Protocol Assessment (SPA) agreement.
• Enrollment in the SOL-R trial is progressing well.
• The FDA provided positive feedback on a potential registrational trial design for AXPAXLI in NPDR.
• The company anticipates that net product revenue on a quarterly basis should increase for the remainder of 2025.

Negatives

• Net revenue decreased by 27.6% compared to the same quarter last year, primarily due to lower DEXTENZA sales.
• The company reported a net loss of $(64.1) million for the quarter.
• Research and development expenses have significantly increased.

Risks

• The company's future performance depends on the success of its clinical trials and regulatory approvals.
• The company faces competition in the market for ophthalmic products.
• The company's cash runway is based on current plans and estimates, which may change.
• The company's existing indebtedness and the ability of the Company's creditors to accelerate the maturity of such indebtedness upon the occurrence of certain events of default.

Future Outlook

The company anticipates increased net product revenue on a quarterly basis for the remainder of 2025 and expects its current cash balance to fund operations into 2028, including through topline data for SOL-1 and SOL-R.

Management Comments

• 'We continue to advance the SOL registrational program for our product candidate AXPAXLI in wet AMD with urgency and precision,' said Pravin U. Dugel, MD, Executive Chairman, President and Chief Executive Officer of Ocular Therapeutix.
• Dr. Dugel stated that the company implemented strategic regulatory updates designed to accelerate the SOL program, enhancing capital and operational efficiencies.
• Dr. Dugel concluded that the company is in an outstanding position to become a leading retina company.

Industry Context

Ocular Therapeutix is focused on the retina space, competing with companies like Regeneron (aflibercept/Eylea) and Novartis (brolucizumab-dbll/Beovu) in the wet AMD market. The company's AXPAXLI aims to provide a longer-lasting treatment option, potentially reducing the frequency of injections compared to existing therapies. The positive feedback from the FDA on the NPDR trial design suggests a potential expansion into a new market segment.

Comparison to Industry Standards

• Regeneron's Eylea, a leading treatment for wet AMD, requires injections every 4-8 weeks, while Ocular Therapeutix is aiming for a 6-12 month dosing regimen with AXPAXLI.
• Novartis' Beovu, another competitor in the wet AMD space, has faced challenges related to safety concerns, potentially creating an opportunity for AXPAXLI if it demonstrates a favorable safety profile.
• The SOL-R trial's non-inferiority margin of -4.5 ETDRS letters is consistent with FDA guidance for wet AMD trials.
• The company's cash runway into 2028 provides a competitive advantage, allowing it to focus on clinical development and commercialization without immediate concerns about funding.

Stakeholder Impact

• Shareholders: The company's financial performance and clinical trial progress will impact shareholder value.
• Employees: The company's growth and development activities will affect employment opportunities and job security.
• Patients: The success of AXPAXLI could provide a new treatment option for wet AMD, NPDR, and DME.
• Customers: Clinicians and patients using DEXTENZA may be affected by changes in pricing and reimbursement.
• Creditors: The company's ability to meet its debt obligations depends on its financial performance.

Next Steps

• Actively planning next steps in the development of AXPAXLI for NPDR and DME.
• Continuing the SOL-1 and SOL-R Phase 3 clinical trials.
• Increasing sales efforts directed towards HOPDs for DEXTENZA.

Key Dates

Keywords

AXPAXLI, Ocular Therapeutix, Wet AMD, NPDR, DME, DEXTENZA, Clinical Trials, Financial Results, SOL-1, SOL-R, Retina, Ophthalmology